logo
Share SHARE
FONT-SIZE Plus   Neg

First Community Bancshares Q1 Profit Edges Down, Yet Tops Estimates

First Community Bancshares, Inc. (FCBC) reported first-quarter net income available to common shareholders of $5.7 million or $0.31 per share, slightly lower from $5.8 million or $0.32 per share last year.

Excluding items, non-GAAP core earnings was $6.2 million or $0.32 per share, compared to $5.4 million or $0.0.30 per share a year ago.

On average, 4 analysts polled by Thomson Reuters expected earnings of $0.27 per share for the quarter. Analysts' estimates typically exclude special items.

Net interest income for the quarter declined to $18.0 million from $18.2 million a year ago. Net interest margin dropped 5 basis points to 3.91 percent from 3.96 percent last year.

Noninterest income dropped to $8.0 million from $9.5 million in the year-ago quarter.

Analysts expected total revenues of $26.46 million for the quarter.

Provision for loan losses for the quarter reduced to $0.9 million from $1.6 million last year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Database startup MongoDB has filed confidentially for initial public offering, aiming to go public before the end of the year, according to TechCrunch. The company, which develops enterprise-grade, open-source software including MongoDB NoSQL database, reportedly has submitted an S-1 filing in the past few weeks. Wal-Mart Stores Inc., the world's largest retailer, reported a decline in second-quarter profit with a significant charge. Adjusted earnings topped analysts' estimates with higher comparable sales. Looking ahead, for the third quarter, the company projects earnings in line or below market view. The company also issued earnings forecast for fiscal 2018. The development of Alzheimer's drugs has been marred by a high failure rate. A U.S. study, which analyzed how the Alzheimer's clinical trials fared during the period of 2002 to 2012, revealed a failure rate of 99.6% compared to a failure rate of 81% for cancer drugs.
comments powered by Disqus
Follow RTT